LENZ Therapeutics (LENZ) Set to Release Earnings on Thursday

Key Points

• LENZ Therapeutics is scheduled to report Q3 2026 results before markets open on October 29. Analysts expect a loss of $0.99 per share and revenue of $4.20 million.
• The company exceeded estimates in its latest quarter, reporting a $1.02-per-share loss versus the expected $1.05 loss and $5.49 million in revenue versus the $2.38 million consensus.
• LENZ shares opened at $3.16 after declining 2.8%, near their 52-week low of $3.06. Analysts have a consensus “Hold” rating, despite an average price target of $23, while the company continues developing VIZZ, a once-daily eye drop for presbyopia.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) is projected to post its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect LENZ Therapeutics to post earnings of ($0.99) per share and revenue of $4.20 million for the quarter. Parties can check the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:30 AM ET.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.03. LENZ Therapeutics had a negative net margin of 586.74% and a negative return on equity of 53.39%. The business had revenue of $5.49 million for the quarter, compared to the consensus estimate of $2.38 million. On average, analysts expect LENZ Therapeutics to post ($4.15) EPS for the current fiscal year and ($3.06) EPS for the next fiscal year.

LENZ Therapeutics Trading Down 2.8%

Shares of LENZ stock opened at $3.16 on Friday. The firm has a market capitalization of $99.29 million, a P/E ratio of -0.77 and a beta of 0.64. LENZ Therapeutics has a 1 year low of $3.06 and a 1 year high of $32.92. The firm's fifty day simple moving average is $4.25 and its 200 day simple moving average is $6.05.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on LENZ. HC Wainwright restated a "buy" rating on shares of LENZ Therapeutics in a research report on Tuesday, July 7th. Piper Sandler cut their price objective on shares of LENZ Therapeutics from $7.00 to $5.00 and set a "neutral" rating for the company in a research report on Monday. Zacks Research raised shares of LENZ Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Thursday, August 13th. Citigroup reiterated a "buy" rating on shares of LENZ Therapeutics in a research note on Wednesday, August 12th. Finally, Weiss Ratings downgraded LENZ Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Wednesday, September 9th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $23.00.

About LENZ Therapeutics

LENZ Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing pharmaceutical therapies for presbyopia, the age-related loss of near vision. The company's approach is designed to improve near visual acuity by using aceclidine, a miotic agent intended to create a pinhole effect that can increase depth of focus while preserving distance vision.

LENZ's lead product candidate, VIZZ, is an aceclidine hydrochloride ophthalmic solution developed as a once-daily prescription eye drop for adults with presbyopia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.